Search Results

Your search for Randy F. Sweis, MD, and Olufunmilayo I. Olopade, MD,Randy F. Sweis, MD, and Olufunmilayo I. Olopade, MD matches 2 pages

Showing 1 - 2

By Randy F. Sweis, MD, and Olufunmilayo I. Olopade, MD / April 10, 2015

Understanding the Role of Immune Function in the Treatment of HER2-Positive Breast Cancer

The addition of trastuzumab (Herceptin) to adjuvant chemotherapy undoubtedly transformed HER2-positive breast cancer from one of the most deadly subtypes to a highly treatable disease. Randomized phase III trials established adjuvant trastuzumab as standard of care in HER2-positive breast...

breast cancer

By Matthew Stenger / April 10, 2015

Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Edith A. Perez, MD, of the Mayo Clinic, Jacksonville, and colleagues found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who...

Nov

Today In Oncology

Search Results

Your search for Randy F. Sweis, MD, and Olufunmilayo I. Olopade, MD,Randy F. Sweis, MD, and Olufunmilayo I. Olopade, MD matches 2 pages

Understanding the Role of Immune Function in the Treatment of HER2-Positive Breast Cancer

Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC